Duo Oncology is an oncology company developing next-generation chemotherapy for solid tumors. Its lead program, DUO-207, consolidates commonly co-administered cytotoxic agents into a single, tumor-targeted prodrug designed to improve intratumoral exposure while reducing systemic toxicity. The program is supported by completed IND-enabling studies, orphan drug designations, and strong preclinical benchmarks versus standard of care. Duo is advancing toward first-in-human studies with a capital-efficient clinical strategy focused on rapid clinical validation and strategic partnering, supported by both strategic pharmaceutical investment and non-dilutive funding.

Eurofins CDMO Alphora, part of an international network of Eurofins Scientific, develops and manufactures small molecule & biologic drug substances and drug products “under one roof” in Mississauga, Ontario, Canada. Our small molecule capabilities include the development and manufacture of API’s and HPAPI’s, oral drug products and API solid-state R&D. Our biologics capabilities include the development and manufacture of mAbs, proteins and ADCs, and Sterile Fill (2026). Established in 2003, our FDA, Health Canada, and Japan PMDA inspected site has over 250 people.

Galibra Neuroscience is a Boston Children’s Hospital-affiliated biotechnology company co-founded by Henry Lee, MPhil, PhD, and Alexander Rotenberg, MD, PhD, dedicated to developing gene therapies for disorders disrupting γ-aminobutyric acid (GABA) signaling, the brain’s primary inhibitory neurotransmitter system.  The company’s initial focus is succinic semialdehyde dehydrogenase deficiency (SSADHD), a rare genetic disorder caused by ALDH5A1 mutations that lead to toxic GABA metabolite accumulation, resulting in intellectual disability, autism features, drug-resistant epilepsy, and other neurodevelopmental issues.  Galibra’s lead candidate, GAL005, is an AAV-based gene replacement therapy delivering a functional human ALDH5A1 gene to the brain, with preclinical studies in mouse models and patient-derived neurons demonstrating efficacy in reversing SSADHD symptoms.  Backed by strong support from the SSADHD patient community, families, and clinicians, Galibra benefits from unique access to natural history data, biomarkers, patient cohorts, and clinical infrastructure to accelerate translation from bench to bedside.
The broader pipeline targets related GABA disorders, including SLC6A1-related conditions, GABA transaminase deficiency, GABA receptor variants, and select drug-resistant epilepsies, Galibra aims to leverage an advanced AAV platform with brain-penetrant capsids (such as Apertura’s TfR1 CapX technology) and shared manufacturing expertise to expand impact across these debilitating conditions.

Geneius Biotechnology is a T cell immunotherapy company focused on therapies for cancer. There is growing evidence for the potential of T cell immunotherapy for successful treatment of cancer patients. Our proprietary approach is distinct and unique from other T cell immunotherapy approaches and promotes the surveillance and destruction of cancer cells by the immune system. Through a transformative academic collaboration we are rapidly translating products from bench to bedside. We are currently developing products for both hematologic and solid cancers through our academic collaboration and expect to start clinical trials by the end of the year.  Pending regulatory approval, our products will be transferred to commercial manufacturing and clinical development programs for multicenter clinical studies. Geneius Biotechnology is privately financed. It operates a laboratory in Natick, Massachusetts (near Boston) and is expanding its network to commercialize T cell immunotherapy globally.

Hua Medicine (HKEX:2552) is a Shanghai-based, commercial-stage biopharmaceutical company advancing innovative therapies for diabetes. Its cornerstone product, dorzagliatin tablets (HuaTangNing), is a global first-in-class glucokinase activator (GKA) and the only GKA approved to date. By targeting the body’s glucose sensor glucokinase, dorzagliatin is designed to restore glucose sensitivity and maintain healthy glycemic control, i.e., glucose homeostasis. Dorzagliatin was approved for commercialization in China in September 2022, and received Hong Kong Department of Health registration approval in February 2026. A second generation GKA currently in clinical development in the United States.

Illumen Therapeutics is pursuing a moonshot for the treatment of cancers by inhibiting the enzyme PARN to increase functional p53, the crucial tumor suppressor protein that acts as the "guardian of the genome". The PARN inhibition strategy represents a breakthrough in oncology drug development and provides a novel mechanism for drugging wild-type p53 that avoids the historical problems exhibited with MDM2 inhibitor efforts. Dysregulation of p53 is a hallmark of nearly all cancers, and successfully drugging p53 has long been the “holy grail” of cancer drug development. The company is at the hit-2-lead/hit expansion stage of PARN inhibitor drug discovery and is working with a European pharmaceutical research partner to broaden PARN inhibition evidence and advance drug discovery efforts. Illumen Therapeutics was spun-out of Roy Parker’s lab at the University of Colorado Boulder and is poised to make a significant impact in the fight against cancer.

Imbrium Therapeutics L.P. (“Imbrium”) is pursuing a novel, first in class antineoplastic agent for the treatment of solid and hematologic cancers, as well as a NCE targeting a novel and distinct receptor system for disorders of the central nervous system and genitourinary tract. Imbrium strives to develop new medicines that serve the unmet needs of patients, physicians, and health systems worldwide.  Imbrium has built a robust and diversified pipeline of investigational drug candidates, and it seeks to actively collaborate with industry and academic partners to identify and advance future impactful medicines.

Sustained Therapeutics is developing a sustained-release drug delivery platform with application across a broad range of conditions, including pain and cancer. The company has developed three products and all are in clinical trials.  The first product is a non-opioid medication for chronic pain that has successfully completed its Phase 2 trial, demonstrating a month of pain relief from a single injection.  The second product is a sustained release oncology medication currently in a Phase 2/3 study in an orphan indication, Upper Tract Urethral Carcinoma. This product delivers a chemotherapy agent directly to the site of the cancer rather than relying on infusion.

Vesselon’s multi-tumor oncolytic virus is a next generation therapeutic platform that can provide complete tumor killing with only one viral vector for every 30 cancer cells. Using AI-logic driven multi-omics of recurrent tumors, patient-specific antigens can be cloned into the vector and delivered to patients in 90 days. Vesselon complements this with a co-formulation delivery platform using an FDA-approved, biophysically activated lipid microsphere that counters tumor defense systems. This combination of a versatile intravenous delivery platform with a powerful cancer therapeutic platform will overtake recurrent solid tumors as they try to evade conventional chemo and immunotherapies.

Zena Therapeutics is a preclinical-stage biotechnology company developing safer, fast-acting anxiety medications to address critical limitations of current treatments. Our lead compound, ZTX-001, is a novel unselective partial GABA-A receptor modulator that delivers the rapid efficacy of benzodiazepines without the risks of fatal overdose or withdrawal syndrome. By utilizing a ceiling effect mechanism, ZTX-001 provides robust anxiolytic benefit while eliminating the respiratory depression that causes over 12,000 benzodiazepine-related deaths annually in the U.S. Backed by exclusive IP from Rutgers University and $1.6M+ in venture and grant funding, Zena is advancing toward IND-enabling studies to bring transformative mental health solutions to millions of patients in need.